Reduced bioavailability and activity of IGF-1 due to increased neuronal IGFBP5 expression in the hippocampus may also reduce AD-associated hippocampal hyperactivity at early stages of AD progression due to reduced IGF-1R activation [4, 16, 78]. The gene discussed is IGF1; the disease is Alzheimer disease.